Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gary E. Stein, Pharm.D., Michigan State University
ClinicalTrials.gov Identifier:
NCT01401010
First received: July 14, 2011
Last updated: May 2, 2012
Last verified: May 2012
  Purpose

Primary: To determine the serum pharmacokinetics (PK) of doripenem in febrile neutropenic patients.

Secondary: Monte Carlo Simulations Tested Against Various Gram-negative Isolates and Reported as Probability of Target Attainment (40% Time (fT)> minimum inhibitory concentration (MIC))


Condition Intervention Phase
Febrile Neutropenia
Drug: Doripenem
Drug: doripenem
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection

Resource links provided by NLM:


Further study details as provided by Michigan State University:

Primary Outcome Measures:
  • Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients [ Time Frame: 1, 4, 6, 8 hours after at least two doses of drug ] [ Designated as safety issue: No ]
    To determine the serum pharmacokinetic volume of distribution of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.

  • Mean (SD) Doripenem Pharmacokinetic (PK) Elimination Rate Constant Parameter in Febrile Neutropenic Patients [ Time Frame: 1, 4, 6, 8 hours after at least two doses of drug ] [ Designated as safety issue: No ]
    To determine the serum pharmacokinetic elimination rate constant of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.

  • Mean (SD) Doripenem Pharmacokinetic (PK) Half Life Parameter in Febrile Neutropenic Patients [ Time Frame: 1, 4, 6, 8 hours after at least two doses of drug ] [ Designated as safety issue: No ]
    To determine the serum pharmacokinetic half life of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.

  • Mean (SD) Doripenem Pharmacokinetic (PK) Clearance of Drug Parameter in Febrile Neutropenic Patients [ Time Frame: 1, 4, 6, 8 hours after at least two doses of drug ] [ Designated as safety issue: No ]
    To determine the serum pharmacokinetic clearance of drug of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.

  • Mean (SD) Doripenem Pharmacokinetic (PK) Area Under Serum Curve (mg*h/L) Parameter in Febrile Neutropenic Patients [ Time Frame: 1, 4, 6, 8 hours after at least two doses of drug ] [ Designated as safety issue: No ]
    To determine the serum pharmacokinetic area under serum curve of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.


Secondary Outcome Measures:
  • Monte Carlo Simulations Tested Against Various Gram-negative Isolates and Reported as Probability of Target Attainment (40% Time (fT) > Minimum Inhibitory Concentrations (MIC)) [ Time Frame: 1, 4, 6, 8 hours after an infusion of doripenem to determine the PK parameters ] [ Designated as safety issue: No ]

    Following determination of pharmacokinetic (PK) parameters from patients with febrile neutropenia, Monte Carlo simulations were then conducted to determine time of serum concentrations above the MIC (40% of the time) against Gram-negative isolates.

    These Gram-negative isolates had a range of minimum inhibitory concentrations (MIC) to Doripenem.



Enrollment: 12
Study Start Date: August 2010
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Doripenem 500 mg
pharmacokinetics/pharmacodynamics
Drug: Doripenem
500 mg every 8 hours
Other Name: Doribac
Active Comparator: Doripenem 1000 mg
pharmacokinetics/pharmacodynamics
Drug: doripenem
1000 mg every 8 hours
Other Name: Doribac

Detailed Description:

Background: Doripenem is a group 2 carbapenem with enhanced in vitro activity against Gram-negative bacteria including Pseudomonas aeruginosa. Currently, there is a paucity of pharmacokinetic/pharmacodynamic data on doripenem in patients with febrile neutropenia.

Objectives: To conduct a pharmacokinetic and safety evaluation of two doses of doripenem in febrile neutropenic patients and provide probability estimates of attaining effective drug exposure against common Gram-negative pathogens.

Methods: We obtained multiple blood samples from 12 adult patients with febrile neutropenia who were receiving either 500 mg or 1000 mg of doripenem IV over 4-hours every 8 hours. Following at least 2 doses, serum concentrations were measured in each subject at 1, 4, 6 and 8 hours after initiation of a dose by a validated HPLC assay. The derived pharmacokinetic (PK) parameters from these serum levels were utilized to perform a 5000 patient Monte Carlo simulation against bacteria with minimal inhibitory concentrations (MICs) of 0.008 to 64 mg/L to determine probability estimates of time of free drug concentration > MIC (fT>MIC).

Results: The mean PK parameters in these patients were a volume of distribution (Vd) of 43.9L, an elimination rate constant (k) of 0.37 hr -1, a total clearance (Cl) of 14.4 L/h, and an area under the concentration-time curve (AUC) of 57.6 mg∙h/L. An optimal probability of target attainment (40% fT>MIC) of 90% was obtained against bacteria with MICs ≤ 2.0 and ≤ 4.0 mg/L with 500 mg and 1000 mg doses, respectively. Adverse events associated with doripenem were not observed in these patients.

Conclusions: The findings from this analysis of doripenem suggest that higher doses as well as prolonged infusions may be necessary to optimally treat selected Gram-negative bacteria (eg. Pseudomonas aeruginosa) in patients with febrile neutropenia

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult neutropenic (< 500 cells) patients who are febrile

Exclusion Criteria:

  • Patients with Creatinine Clearance < 30 ml/min or allergy to carbapenems will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01401010

Locations
United States, Michigan
Sparrow Hospital
Lansing, Michigan, United States, 48910
Sponsors and Collaborators
Gary E. Stein, Pharm.D.
Investigators
Principal Investigator: Gary Stein, PharmD Michigan State University
  More Information

No publications provided

Responsible Party: Gary E. Stein, Pharm.D., Professor of Medicine and Pharmacology, Michigan State University
ClinicalTrials.gov Identifier: NCT01401010     History of Changes
Other Study ID Numbers: DORIBAC4006a
Study First Received: July 14, 2011
Results First Received: March 6, 2012
Last Updated: May 2, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Michigan State University:
neutropenia
doripenem

Additional relevant MeSH terms:
Febrile Neutropenia
Fever
Neutropenia
Agranulocytosis
Body Temperature Changes
Hematologic Diseases
Leukocyte Disorders
Leukopenia
Signs and Symptoms

ClinicalTrials.gov processed this record on October 23, 2014